Sunovion (United Kingdom)
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Sunovion (United Kingdom), United Kingdom, covering academic research published from 2000 to 2023. Read More.
Open Access Percentage
45%
Total
Publications
94
Total Open
Publications
42
Total
Citations
673
Open Access
Percentage
45%
Total
Publications
94
Total Open
Publications
42
Total
Citations
673
Breakdown
Publisher Open
13%
Both
23%
Other Platform Open
9%
Closed
55%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 15%
5
Hybrid 32%
11
No Guarantees 53%
18
Other Platform Open
Domain 87%
26
Public 10%
3
Other Internet 10%
3
Institution 7%
2
Preprint 3%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 26 |
Europe PMC | Domain | 8 |
Semantic Scholar | Public | 3 |
Unknown Repository | Other Internet | 2 |
University of Leeds, The University of Sheffield, University of York - White Rose Research Online | Institution | 2 |
Research Square | Preprint | 1 |
Queen Mary University of London - Queen Mary Research Online | Institution | 1 |
Imperial College London - Spiral | Institution | 1 |
DOI | Other Internet | 1 |